So far, EGFRi have been the 1st line standard in EGFR+ NSCLC. Landscape of resistance will probably change with the arrival of ami+laz option, but, until now dual antiEGFR/MET inhibition should be considered upon IIIgen TKI progression.

Winning the The Nobel Prize is the honour of a lifetime and the realisation of a lifelong dream - it still hasn’t really sunk in yet. With AlphaFold2 we cracked the 50-year grand challenge of protein structure prediction: predicting the 3D structure of a protein purely from its

NUT Carcinoma is an ultra-rare entity with a NUTM1 fusion, diagnosed by a simple IHC NUT+ (can look like a squamous lung cancer in a never smoker pt). Previously known as midline carcinoma, its prognosis is extremely poor. Lurbinectedin appears promising! annalsofoncology.org/article/S0923-…

Send your applications!! This is a very well established program I have the honor to co-chair with Rami Manochakian MD, FASCO Cancer Education and with an amazing mentoring group! Anne Tsao, MD, MBA Marina Garassino Dr. Luis E. Raez Jyoti D Patel Balazs Halmos Alona Zer Dr. Amy C. Moore Triparna Sen (Sen-Lab) LudaBazhenovaMD and more!

New one from our MTB showing the caveats of the "new era" in oncogene+NSCLC: overcoming complex/multiple bypass resistance through combination treatments might make sense biologically, but is often clinically challenging. Arianna Marinello, MD jtocrr.org/article/S2666-…

L'Institut Curie suspend aujourd'hui son activité sur X (anciennement Twitter). Cette décision fait suite à l'évolution éditoriale du réseau X qui est devenue incompatible avec nos valeurs : humanisme, respect, ouverture et excellence scientifique.

Bravo Max Cani for getting the "best poster" award for his work on Lung Cancer Screening in Italy 🇮🇹 #ELCC2025

Great talk by ⁦Benjamin Besse⁩ on de-escalation strategies in oncology. Young fellow, if you missed it, check it on the #ELCC25 platform. We should change our mind and aim to de-escalade whenever possible.

Kinase Domain Duplications (KDD) are complex rearrangements and rare resistance mechanisms to kinase inhibitors. We report the first case of acquired BRAF-KDD in a patient with #BRAF V600E+ #NSCLC treated with dabrafenib-trametinib. JCO Precision Oncology ascopubs.org/doi/10.1200/PO…

🚨 New preprint drop! MOSAIC builds a pan-cancer spatial + single-cell multi-omics atlas of thousands of tumors, exposing the fine-grained mosaic of intra-tumoral heterogeneity and immune niches. A game-changer for #PrecisionOncology and data-hungry AI models. More to come (much

🔹 Lodovica Zullo presented yesterday the results of a pathomics-based prediction analysis of thymic epithelial tumor subtypes.  @asco #ASCO25 #ASCO

🔹 Martina pagliuca presents a hierarchical clustering analysis to dissect behavioural symptoms in early stage breast cancer. a work conducted on CANTO #breastcancer #symptomscience. #ASCO25 #ASCO

#MCCRWorkshop Faculty & Fellows, class of 2025! Since 1999, this workshop has fostered innovation, collaboration, and groundbreaking research in clinical cancer. #EORTC ESMO - Eur. Oncology AACR

Up to 50% of patients with metastatic cancer develop lung metastases, linked to poor prognosis and impaired quality of life. Our Nature Reviews Disease Primers article unpacks biology, diagnosis & treatment strategies. Lodovica Zullo Gustave Roussy nature.com/articles/s4157…

Thank you for the opportunity to contribute to this paper Benjamin Besse . Huge congrats to Lodovica Zullo and all co-authors!

Our NEW Primer on Lung metastases is live today! By Zullo, Filippiadis, Hendriks, Portik, Spicer, Wistuba & Besse. Check it out here: nature.com/articles/s4157…

Get Primed on Lung metastases with our NEW PrimeView! FREE to download this week! nature.com/articles/s4157…

Italian National Team at #WCLC2025 Arianna Marinello, MD Roberto Ferrara Max Cani Giulia Mazzaschi Federica Pecci Andrea De Giglio, MD PhD Carlo Genova and many others 🇮🇹🍕

Vietare l’educazione alla sessualità nelle scuole medie non tutela i minori, ma compromette la loro salute e sicurezza per: 👉aumento gravidanze adolescenziali non intenzionali 👉maggiore incidenza infezioni sessualmente trasmissibili 👉minore capacità di riconoscere e